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Abstract
Background: In acute renal failure, a pronounced net protein catabolism occurs that has long
been associated with corticoid action. By competitively blocking the glucocorticoid receptor with
the potent antiglucocorticoid RU 38486, the present study addressed the question to what extent
does corticoid action specific to uremia cause the observed muscle degradation, and does inhibition
of glucocorticoid action reduce the protein wasting?
Methods: RU 38486 was administered in a dose of 50 mg/kg/24 h for 48 h after operation to fasted
bilaterally nephrectomized (BNX) male adult Wistar rats and sham operated (SHAM) controls.
Protein turnover was evaluated by high performance liquid chromatography (HPLC) of amino acid
efflux in sera from isolated perfused hindquarters of animals treated with RU 38486 versus
untreated controls.
Results: Administration of RU 38486 reduces the total amino acid efflux (TAAE) by 18.6% in
SHAM and 15.6% in BNX and efflux of the indicator of net protein turnover, phenylalanine (Phe)
by 33.3% in SHAM and 13% in BNX animals as compared to the equally operated, but untreated
animals. However, the significantly higher protein degradation observed in BNX (0.6 ± 0.2 nmol/
min/g muscle) versus SHAM (0.2 ± 0.1 nmol/min/g muscle) rats, as demonstrated by the marker of
myofribrillar proteolytic rate, 3-Methylhistidine (3 MH) remains unaffected by administration of RU
38486 (0.5 ± 0.1 v. 0.2 ± 0.1 nmol/min/g muscle in BNX v. SHAM).
Conclusion: RU 38486 does not act on changes of muscular protein turnover specific to uremia
but reduces the effect of stress- stimulated elevated corticosterone secretion arising from surgery
and fasting. A potentially beneficial effect against stress- induced catabolism in severe illness can be
postulated that merits further study.
Background
As part of the complex uremic metabolic syndrome, pro-
nounced disturbances of carbohydrate and lipid metabo-
lism are commonly observed, as are pathologic changes of
amino acid and protein turnover [1]. An increased net
protein degradation in uremia was seen as early as 1949
by Persike and Addis[2], and in the same year, Bondy et al.
[3] showed that adrenal hormones are involved therein.
These early findings were validated in the late eighties by
Schäfer et al. [4,5] who postulated a leading role for gluco-
corticoids as cause of the observed changes. Schäfer et. al
used the experimental approach of inhibiting activation
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of the glucocorticoid receptor by enteral application of the
potent glucocorticoid antagonist RU 38486 in acutely ure-
mic rats [6] and found a decrease both in the accumula-
tion of 3-methylhistidine, an amino acid that is produced
in actomyosine catabolism and is not further metabo-
lized, and in the activity of myofibrillar protease. How-
ever, while an effect of RU38486 on liver gluconeogenesis
and urea synthesis in uremia could be demonstrated [7,8],
so far there is no proof of a direct action of RU38486 on
muscle metabolism in uremia. To address this problem,
the present study made use of the classical experimental
design of the isolated perfused hindquarter of the rat [9],
in which roughly 40% of the rat body's total muscle mass
can be evaluated under closely defined in vitro
conditions.
With this experimental design and by comparing sham-
operated and bilaterally nephrectomized animals, the
present study looked at the question to what extent does
corticoid action specific to uremia cause the observed
muscle degradation, and does inhibition of glucocorti-
coid action reduce the protein wasting?
Methods
Animal experimentation was carried out on male Wistar
rats, aged 11–15 weeks, weighing 217–225 g, from the
animal experimentation facilities of Heinrich Heine Uni-
versity, Düsseldorf. Permission to use animals for experi-
mentation was given by Regierungspräsident Düsseldorf,
file nr. 26.4203.1-217/87 according to German federal
law. Surgery for nephrectomy, sham nephrectomy and
preparation for perfusion was carried out under narcosis
with hexobarbital (EVIPAN- Na: 15–20 mg/ 100 g BW).
Bilateral nephrectomy was performed using a dorsal
access, ligation of renal vessel string, and excision of the
kidney, leaving the adrenal glands in place. Sham oper-
ated animals underwent the same manipulations except
for the ligation and excision. After surgery, animals were
fasted for 48 h until perfusion. Nephrectomized animals
had access to drinking water on the day of surgery for 8
hours, then were deprived of liquid to avoid lung edema.
Sham animals had free access to drinking water
throughout.
Animals were randomly assigned to one of four groups:
bilaterally nephrectomized (BNX) and sham operated
(SHAM) treated with RU38486 and untreated BNX and
SHAM animals. For treatment, RU38486 was dissolved in
phenylmethanol, then mixed with sesame oil to form a
milky suspension which was injected into subcutaneously
into the lateral abdomen in three subdoses within 24 h,
adding up to a total dose of 5 mg/100 g/BW.
48 h after initial surgery, animals were narcotized and pre-
pared for perfusion as previously described[10].
The hindquarter was linked to the recirculation system
after full passage of 70 ml of pre- perfusion medium, as
shown in illustration 1. The pre- perfusion medium was
discarded and not used for the recirculation experiment.
The perfusion was carried out with a half- synthetic
medium on the basis of Krebs- Ringer- bicarbonate buffer
(KRB), pH 7.38 [11]. Oxygen carriers were calf erythro-
cytes prepared from fresh calf blood sampled two days
before experimentation and maintained with 300 mg/l
Ampicillin and 220 ml/l citric acid/ glucose stabilizer.
Bovine albumine maintained the physiologically correct
oncotic pressure. 10-6 mmol/l phentolamine were added
to avoid vessel contractions.
During perfusion, the arterial pH and perfusate oxygena-
tion were monitored using a pH- meter and a total oxygen
content analyzer (LEX- O2- CON, Lexington Instr., Mass.,
USA). At the beginning and end of perfusion, plasma sam-
ples were frozen for amino acid analysis. Amino acid anal-
ysis by HPLC was carried out using 25 µl of deproteinized
perfusate sample, mixed with o-phthaldialdehyde (OPA)/
3-mercaptopropionic acid to form OPA- adducts that were
separated on a reversed phase column and measured by
fluometry. Quantification was done by comparison with
a standard amino acid mix including 3-methylhistidine.
Of the 20 proteinogenic amino acids, cysteine, proline,
and asparic acid were not included in HPLC analysis.
Statistical analysis was done using the "Student" t- test for
ungrouped, non- paired data with f = n1 + n2-2 and a sig-
nificance level of p < 0.05.
Results
Loss of body weight (BW)
During the 48 h fasting period between operation and
perfusion, animals had a pronounced loss of BW (table
1). In SHAM, it was 35.5 ± 5.3 g; administration of RU
38486 reduced this to 27.6 ± 5.9 g (p < 0.05). Nephrect-
omized animals demonstrated a much less pronounced
loss of BW due to a significant increase in tissue hydrata-
tion (Table 2). RU 38486 reduces the weight loss in
nephrectomized animals, too; however, this effect is
much less pronounced and lacks statistical significance
(BNX 15.7 ± 4.8 g, BNX + RU 12.2 ± 4.8 g).
Oxygen utilization and development of acidosis
Oxygen utilization in the perfused muscle tissues is
roughly the same in all four groups (data not shown) and
equal to in vivo data previously reported [12] from rats
after 24 hour fasting. As expected, pH dropped signifi-
cantly lower during perfusion in the nephrectomizedBMC Nephrology 2005, 6:2 http://www.biomedcentral.com/1471-2369/6/2
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groups (SHAM: 7.378 ± 0.033, BNX 7.321 ± 0.018, p =
<0.01; SHAM + RU 7.4 ± 0.031, BNX + RU 7.312 ± 0.013,
p < 0.001).
Parameters of amino acid and protein metabolism
Total amount and spectrum of amino acids released during
reperfusion: During perfusion, amino acids are released in
varying amounts as shown in ill. 2. Nephrectomized ani-
mals (BNX) showed a general increase in amino acid
release. This, however, is significant only in a few individ-
ual amino acids. The total amino acid efflux increases by
10,4 % (p = 0.05) without qualitative change. Notable
exception is glycine, which is released to a lesser amount
in nephrectomized animals. Amino acid release after treat-
ment with RU 38486: Nephrectomy equally increases the
amino acid efflux in animals treated with RU 38486 by
14.4% (p < 0.05) without change in spectrum. The total
efflux of amino acids, however, is significantly reduced in
the comparison SHAM/ SHAM+RU (-18.6%, p < 0.05)
and BNX/ BNX+RU (-15.6%, p < 0.001). Release of 3-meth-
ylhistidine: 3-methylhistidine, a derivate of histidin mainly
from actin and myosin in sceletal muscle and intestinal
mucosa [13], is not reutilized after proteolysis, but
excreted via the kidney as 3-methylhistidine or N- acetyl-
3-methylhistidine. During reperfusion of sham- nephrec-
tomized animals, 3-methylhistidine is released from the
hindquarter to a small amount that is incresed by roughly
300% in the nephrectomized animals. Administration of
RU38486 has no effect on 3-methylhistidine efflux. (table
3).
Discussion
Background
Acute renal failure is a catabolic state, and unfortunately
the inherent acceleration of protein breakdown cannot be
suppressed effectively by provision of exogenous nutri-
tional substrates [14]. The situation is multicausal.
Unspecific mechanisms induced by the process of acute
disease, underlying illness and associated complications
are just one side of the problem. On the other, one
Table 1: Body weight (BW) at day of surgical intervention (OP) and perfusion (EX). Values are gram ± standard deviation. No 
significant intergroup differences.
BW [g] at OP BW [g] at EX Weight loss [g]
SHAM (n = 6) 223.67 ± 8.02 188.17 ± 7.28 35.5 ± 5.3
BNX (n = 6) 217.33 ± 13.81 201.67 ± 11.91 15.7 ± 4.8
SHAM + RU (n = 5) 223.60 ± 9.21 196.00 ± 9.70 27.6 ± 5.9
BNX + RU (n = 5) 225.20 ± 5.36 213.00 ± 7.35 12.2 ± 4.8
Table 2: Dry weight (DW) in % of total tissue weight and hydration (Hy) at day of perfusion in ml/ g of total tissue weight. Average 
values ± standard deviation. Intergroup differences with significance levels of: *p < 0,001; #p < 0,05.
SHAM* BNX* SHAM + RU# BNX + RU#
n 6655
DW [%] 24.41 ± 1.46 21.07 ± 0.98 24.26 ± 1.14 22.10 ± 1.46
Hy [ml/g] 0.761 ± 0.015 0.795 ± 0.010 0.762 ± 0.012 0.784 ± 0.015
Table 3: Total amino acid efflux (TAAE) and release of 3-methyl histidine (3 MH) in serum from isolated perfused rat hindquarter at 
60 min. perfusion. Values given in nmol/min/g muscle + standard-deviation. Intergroup differences with significance of: #p < 0,01; *p < 
0,005; ~, $p < 0,001.
SHAM BNX SHAM + RU BNX + RU
n 6655
TAAE 65.05 ± 5.88* 71.83 ± 5.02# 52.98 ± 2.96* 60.61 ± 5.62#
3 MH 0.2 ± 0.09~ 0.55 ± 0.15~ 0.18 ± 0.06$ 0.53 ± 0.07$BMC Nephrology 2005, 6:2 http://www.biomedcentral.com/1471-2369/6/2
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observes specific uremic effects, insulin resistance, hormo-
nal derangements, metabolic acidosis, circulating pro-
teases and other inflammatory mediators together with
effects induced by the acute loss of renal function and the
type and intensity of renal replacement therapy [1,15-17].
One factor that has for long been associated with the dis-
turbances of protein metabolism is glucocorticoid action.
The first observations date back to the nineteen-forties,
when Persike and Addis [2] reported an increased urea-
nitrogen production in experimental uremia, and Bondy
and coworkers [3] demonstrated that adrenal hormones
were involved in this dysregulation. Half a century later, it
is still not fully understood to what extent steroid hor-
mone action is responsible for the catabolic situation
observed in renal insufficiency[18]. It has been shown
that administration of high doses of glucocorticoids to
adrenalectomized rats resulted in decreased protein syn-
thesis, increased protein degradation, and a negative
nitrogen balance [19]. In patients with chronic renal fail-
ure, a positive correlation between muscle proteolysis and
the plasma cortisol level has been observed [20]. The in
vivo influence of both glucocorticoids and metabolic aci-
dosis on muscle proteolysis has been elucidated in whole-
body leucine turnover studies in adrenalectomized rats
[21]. These findings indicate that glucocorticoids play an
important role in net protein degradation. Price formu-
lated this so: "glucocorticoids are required but not directly
responsible for the acidosis-induced increase in the
mRNAs encoding proteins of this degradative
pathway"[22].
Experimental approach
In order to evaluate the relative importance of glucocorti-
coid action on protein metabolism in acute renal failure,
an experimental setting was chosen that allowed to study
glucocorticoid action indirectly by selective blockade of
the glucocorticoid receptor with the potent antiglucocor-
ticoid RU38486, a substance that binds to the receptor
without activating the further process of transcription
[23]. Parenteral administration of a total of 50 mg/kg BW/
d of RU38486 allowed to avoid additional irritation of the
animals by a gastric catheter in the postoperative phase.
Relevant action of RU38486 has been observed in enteral
substitution at a dose of 20 mg/kg BW/d [6]. The degree
to which RU 38486 blocks the glucocorticoid receptor
depends very much on the mode of application, and the
target tissue. While a recent study[24] shows that 80% of
glucocorticoid receptors are blocked in rat muscle follow-
ing oral application of mifepristone of 50 mg/ kg BW, Kim
et al.[25] demonstrated effective blocking of glucocorti-
coid receptors in rat brain following subcutaneous appli-
cation of 80 mg/ kg over two days. Schaefer et al.[6], on
whose experimental set- up the present study was mod-
eled, had reported significant effects of an oral dose of 20
mg/ kg on muscle. In view of this, the choice for the exper-
imental procedure seems justified as the present study
uses a substantially higher dose.
The isolated perfusion procedure introduced by Ruder-
man[9] is well established for the representative study of
muscle metabolism. In this setting, the perfused muscle
mass is approximately 40% of the total muscle mass. Tak-
ing into consideration the different metabolic require-
ments of the perfused tissues, roughly 90% of oxydative
metabolism occurs in the muscle[12], making this experi-
mental setting truly a skeletal muscle preparation that per-
mits the observation of even very discrete metabolic
changes during reperfusion.
In the given experimental setting, it is difficult to account
for the in detail contribution of protein degradation,
amino acid intermediate metabolism, and protein synthe-
sis. Factors that modify the efflux are transport systems in
the cell membrane [26-28], which can be concentration-
dependent (system L) or acting against the concentration
gradient (system A), and the intermediary metabolism
within the muscle cells[29]. Numerous previous assess-
ments of the metabolic situation in the isolated perfused
hindlimb demonstrate that these factors are relatively
minor contributors, while amino acid efflux is nearly
exclusively characterized by the net balance of protein
metabolism both in anabolic and catabolic situa-
tions[12,30-34]. It is mostly due to changes in skeletal
muscle, with only minor contributions from other tissues
in this preparation [35-37].
Results
Sham- operated animals are catabolic at the time of per-
fusion, having lost about 36 g BW (see results), which is
approximately 16% of initial BW. Rats of this age are still
growing, with an increase of approx. 5 g/ day (2–3%
BW)[38]. The weight loss is due to both lipolysis[39] and
protein loss[40], which causes the typical increase of
amino acid release in the hindquarter of fasting rats[12].
Compared to data[34] from non- operated rats fasted for
48 hours under otherwise identical conditions, the total
amino acid release is increased by 30% in the sham- oper-
ated rats described here. While nephrectomy increases the
amino acid release by approximately 15%, the relative
decrease of amino acid release following administration
of RU 38486 is similar in both nephrectomized and
sham- operated animals. This indicates a stress- accentu-
ated adaptation to fasting caused by corticosteron secre-
tion[41] increased beyond the normal range, with a
further effect of uremia. Increased amino acid serum con-
centrations during fasting are mostly due to an inhibition
of protein synthesis[42], although proteolysis mainly of
myofibrillary proteins does play a role[43]. However, cor-
ticosterone is only one of several effectors at play. RUBMC Nephrology 2005, 6:2 http://www.biomedcentral.com/1471-2369/6/2
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38486 affects neither acidosis nor lactate/ pyruvate ratio.
Both factors may contribute to the continuously increased
amino acid release. In the case of acidosis, this may be due
to an action on acid inhibitable transporters such as sys-
tem A which reduce the supply of nutrients to the
cells[28]. Another possible mechanism is through inhibi-
tion of leptin by acidosis[44], which in neutral pH might
counteract muscle wasting[45]. Balancing acidosis in
chronically uremic rats with increased corticosterone
secretion inhibited protein degradation, but had no effect
on the defective protein synthesis[21]. More recently, RU
38486 was shown to be ineffective in blocking acid- medi-
ated protein degradation as its action is only an indirect
one, mediated via insuline- like growth factor I (IGF-
I)[24,46]. These findings indicate that RU 38486 acts
through an inhibition of the corticosterone- mediated
decrease of protein- synthesis without affecting other fac-
tors that act predominantly on the level of protein degra-
dation. While all these and more factors contribute to the
muscle degradation seen in excess glucocorticoid situa-
tions, the mechanisms responsible in ultima causa remain
still unclear[18]. Nephrectomy enhances the catabolic sit-
uation: the total amino acid efflux is increased by roughly
15% compared to sham- operated animals. The relative
increase of amino acids that are not metabolized, such as
phenylalanin and tyrosin, indicates that this effect is due
to the acute and complex metabolic situation of uremia,
without differenciating between inhibition of protein syn-
A: Isolated rat hindquarter preparation Figure 1
A: Isolated rat hindquarter preparation. The perfused muscle mass is below the dotted line. The tail is clamped off. B: Recircu-
lating perfusion system. Heart piece is the oxygenator (1), wherein the medium is gassed (95% O2, 5% CO2) and from where it 
is pumped (3) up via a filter (nylon mash, 20 µm width) (2) and pH and pO2 probes (4) to attain hydrostatic pressure of 80 mm 
Hg (5) before entering the hindquarter (6). Intermediate sampling and pH adjustment can be carried out if necessary (7).BMC Nephrology 2005, 6:2 http://www.biomedcentral.com/1471-2369/6/2
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thesis and stimulation of protein degradation. A multi-
tude of effectors partake in this metabolic turmoil [15], of
which glucocorticoids have been accused of playing a
leading role [47]. At first sight, this opinion is supported
by the finding that isolated hindquarters of animals
treated with RU 38486 show a significant reduction of
total amino acid efflux (16–19%, p < o.05- p <0.001)
compared to untreated animals that underwent the same
surgical procedure, indicating that RU38486 inhibits
some common degrading influence on protein
metabolism.
By contrast, in the comparison of the two groups treated
with RU38486, the amino acid release remains increased
in nephrectomized animals, albeit to a lesser extent,
stressing the very point that glucocorticoids are only one
of several factors that contribute to the net protein wast-
ing. Chronically uremic rats with increased corticoster-
one- secretion [48] showed a less pronounced increase in
protein degradation when acidosis was balanced while
the defective protein synthesis remained unchanged. In
the present experimental setting, acidosis evolving during
perfusion was not corrected for. Acidosis and glucocorti-
coid action are seen as concomitant factors in the activa-
tion of the ubiquitin- proteasome pathway of muscle
proteolysis [49], and a pH- responsive element in the pro-
moter region for the ubiquitin- proteasome pathway has
been reported [47]. In the situation of uncorrected acido-
sis, it therefore seems likely RU 38486 may have had an
inhibitory effect on the corticoid- induced decrease in pro-
tein synthesis without influencing the proteolytogenic
effects of other putative agents.
This presumption is supported by the finding that RU
38486 had no effect on the efflux of 3-methylhistidin.
While this result is in contrast to Schäfer et al. [6,8], Lowell
et al. found no reduction of the efflux of 3-methylhistidin
after adrenalectomy in the perfused hindquarter of fasted
animals [50], and in rats with chronic uremia, RU38486-
resistant protein catabolism with unchanged release of 3-
methylhistidin has been demonstrated in vivo by Teschner
[51]. As responsiveness of protein synthesis and degrada-
tion to amino acid availability seem to be regulated differ-
entially [52] and activation of glucocorticoid- mediated
proteolysis occurs only at relatively elevated hormone lev-
els [53] compared to the inhibition of protein synthesis
[54], it seems possible to speculate that RU38486 may
have a more pronounced effect on net protein catabolism
at substantially higher doses.
The presented data fail to show that RU38486 inhibits
glucocorticoid action in the specific uremic setting while
Release rate of amino acids (nmol/ min/ g muscle) from isolated perfused rat hindquarter Figure 2
Release rate of amino acids (nmol/ min/ g muscle) from isolated perfused rat hindquarter. Error bars indicate standard devia-
tion. The figure is based on tables 4 and 5 which give the p-values for the comparison between sham- operated and nephrect-
omized animals (table 4) and RU 38486 untreated and treated groups (table 5), respectively.BMC Nephrology 2005, 6:2 http://www.biomedcentral.com/1471-2369/6/2
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it clearly reduces the elevated net protein catabolism com-
pared to non- operated animals. This suggests that gluco-
corticoid mediated protein wasting in acute uremia is
rather a by- product of the overall stress, in the present
experimental setting caused by surgery and fasting, than
due to an independent action specific to uremia.
While this finding abolishes hopes to counteract muscle
wasting in uremia by administration of an anticorticoid
drug and indirectly rather stresses the well described[55]
clinical importance of a balanced acid- base status, it may
open speculation about the usefulness of RU486 in post-
traumatic states and severe illness.
Conclusion
Both sham- operated and nephrectomized animals show
an increase in net protein catabolism. RU38486 clearly
reduces the net protein wasting in both groups, but the
increase in net protein catabolism observed over sham-
operated animals remains unchanged in nephrectomized
rats. The effect of antiglucocorticoid RU38486 may be
attributed to an inhibition of fasting and operative stress-
induced cortisol action which, even when within the
physiological range, promotes increased protein turnover
[56], and to a protective effect against the inhibition of
protein synthesis. While RU38486 had no effect on net
protein catabolism that could be specifically attributed to
uremia, the demonstrated anticatabolic effectiveness in a
stress accentuated metabolic situation should be studied
more closely. Possible targets for therapeutic application
under this aspect include post- traumatic states and severe
illness.
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